Do More With Reuters
Partner Services

Drugmaker ills to drive growth, deals in lab sector

Thu Jul 24, 2008 3:50pm IST
 
Email | Print | | Single Page
[-] Text [+]

By Deepa Seetharaman

NEW YORK (Reuters) - A strong five-year run by companies that specialize in pharmaceutical testing shows no sign of slowing as struggling drug makers farm out even more business to them in a trend that should drive consolidation.

Drug companies stand to save millions of dollars by outsourcing clinical trials to little known contract research organizations, or CROs, because that lets them avoid hiring researchers and building laboratory space of their own.

Some 25 percent of all pre-clinical drug testing is already outsourced to CROs. Faced with stringent regulations, mounting patent expirations and sinking sales and profits, drug makers are expected to rely on CROs more heavily in years to come.

"We will get to 50 percent in three years," said Isaac Ro, analyst at Leerink Swann. "We're in the first two, three innings of significant outsourcing."

Outsourcing of clinical trials is also expected to double within five years, Ro said. In 2007, late-stage development accounted for about $9 billion in CRO revenue and early-stage trials represented about $4.5 billion.

The strong outlook has helped lift shares of CROs like Covance Inc and Parexel International Corp despite the turmoil in the stock market this year.

In the next three years, analysts expect to see a wave of consolidation as larger CROs absorb more specialized companies to boost their capacity to run trials and test drugs. Larger and more diversified CROs will likely see drug companies divest portions of their business to them.

"Drug companies' budgets are under quite a bit of pressure," Jefferies analyst David Windley said. "That pressure contributes to strong outsourcing."   Continued...

Dubai Debt Fears

Villas are seen on the The Palm, Jumeirah, with Atlantis, The Palm, under construction on the breakwater (crescent), May 3, 2008.  REUTERS/Jumana El Heloueh

Banks outside the Gulf played down their exposure to Dubai debt, after fears the emirate could default and even derail world economic recovery prompted a sell-off in global markets.  Full Article | Slideshow 

India Investment Summit 2009
India Investment Summit 2009

Top executives and bankers discuss their own plans and the broader opportunities and challenges for India.  Full Coverage 

People stroll outside the Taj Mahal hotel ahead of the first anniversary of the militant attacks in Mumbai, November 24, 2009.  REUTERS/Punit Paranjpe
Investors worry about another attack

The risk of militants striking again worries investors who fear that a second attack similar to last year's Mumbai raids could shake the economy.  Full Article | Full Coverage 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

road to Copenhagen

BLOGS

Photo
Calculated Move

Reliance aims big with $12 bln bid for LyondellBasell.  Blog 

SHOWCASE

Capital Raising
Capital Raising

Analysis - China banks' rush for billions could trip markets.  Full Article 

 
Photo
Bonus Payout

"Bonus" has become a dirty word on Wall Street.  Full Article 

 
Bubble trouble?
Bubble trouble?

With the BSE Sensex at around 17,000 points, are the Indian equity markets looking at a possible bubble?   Commentary 

 
Funding Blues
Funding Blues

A popular tactic used by Indian brokerages to raise money for rich clients is likely to be banned.  Full Article 

 
Recovery Path
Recovery Path

Indian techie logging out of downturn gloom.  Full Article 

 
Central Banks Cautious
Central Banks Cautious

Reuters tracks the policies of the world's top central banks as the debate over global economic recovery rages on.   Full Coverage 

 
Risky Proposal
Risky Proposal

Rupert Murdoch courts trouble if he blocks Google on news.  Full Article